Table 1.
Characteristics of the Study Cohorts
| Characteristic | Progressors | LTNP | Pediatric |
|---|---|---|---|
| No. | 483 | 169 | 122 |
| Age, y, median (IQR) | 37 (31–43) | 42 (39–42) | 14 (9–17) |
| Age at diagnosis, y, median (IQR) | 35 (29–42) | 25 (22–31) | 0 |
| Sex (male) | 383 (79) | 111 (66) | 51 (42) |
| Transmission risk (sexual) | 389 (81) | 35 (21) | 0 |
| Time since diagnosis, y, median (IQR)a | 0.4 (0.1–1.0) | 15 (13–19) | 14 (9–17) |
| CD4 T-cell count, cells/µL, median (IQR) | 365 (200–548) | 721 (552–966) | 843 (653–1166) |
| CD4 nadir, cells/µL, median (IQR) | 246 (126–337) | 521 (390–657) | 418 (205–636) |
| Viral load, log10 HIV-RNA copies/mL, median (IQR) | 4.5 (3.7–5.1) | 2.0 (1.7–3.2) | 1.5 (1.3–1.7) |
| Naive for antiretroviral treatment | 337 (70) | 169 (100) | 0 (0) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; LTNP, long-term nonprogressor.
aTime since diagnosis is time since infection in the pediatric cohort.